Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805151 | 0.82 | KMT2A (0.42) | KMT2AMALT1TLR2TLR1TDP1 | |
| SCHEMBL14769417 | 0.77 | MALT1 (0.46) | KMT2AMALT1TPSAB1TPSD1TPSG1 | |
| SCHEMBL732427 | 0.75 | KMT2A (0.68) | KMT2AMALT1TLR2TLR1TPSAB1 | |
| SCHEMBL5557644 | 0.75 | KMT2A (0.60) | KMT2AMALT1TLR2TLR1CASP3 | |
| SCHEMBL15684645 | 0.73 | KMT2A (0.52) | KMT2AMALT1TLR2TLR1TDP1 | |
| SCHEMBL13631378 | 0.73 | KMT2A (0.65) | KMT2AMALT1TLR2TLR1CASP3 | |
| SCHEMBL29625033 | 0.73 | KMT2A (0.65) | KMT2AMALT1TLR2TLR1CASP3 | |
| SCHEMBL30678165 | 0.72 | KMT2A (0.57) | KMT2AMALT1TLR2TLR1CASP3 | |
| SCHEMBL13247459 | 0.72 | KMT2A (0.57) | KMT2AMALT1TLR2TLR1CASP3 | |
| SCHEMBL28227637 | 0.72 | KMT2A (0.57) | KMT2AMALT1TLR2TLR1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11400079-B2 | Antibacterial monobactams | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-08-02 | — | — | US | disclosed |
| US-20200330438-A1 | ANTIBACTERIAL MONOBACTAMS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11400079-B2 | Antibacterial monobactams | MGAM, BBOX1, MGAM2 | KMT2A 335/4885MALT1 1342/4885TLR2 522/4885 |
| US-20200330438-A1 | ANTIBACTERIAL MONOBACTAMS | MGAM, BBOX1, MGAM2 | KMT2A 335/4885MALT1 1342/4885TLR2 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.